Abstract: A solid formulation for buccal or oral administration which contains a proteinaceous physiologically active substance as an active ingredient, as well as collagen and a water-soluble additive, said formulation being characterized by being porous and having a good disintegration property, and a preparation thereof are provided.

Abstract: The present invention relates to a sustained-release injection, which comprises a suspension of a powder comprising an active ingredient and a pharmaceutically acceptable biodegradable carrier (e.g. proteins, polysaccharides and synthetic high molecular compounds, preferably collagen, atelocollagen, gelatin, and a mixture thereof) in a viscous solvent for injection (e.g. vegetable oils, polyethylene glycol, propylene glycol, silicone oil, and medium-chain fatty acid triglycerides). The sustained-release injection can release the active ingredient at an effective level for a long period of time when injected.

Abstract: A controlled release formulation which comprises a compound selected from the group consisting of organic acidic compounds and acid anhydrides or esters capable of generating one of the organic acidic compounds through hydrolysis together with an active ingredient and collagen as a carrier, said formulation being capable of exhibiting a predetermined release profile of the active ingredient. A process for producing said formulation is also provided.

Abstract: A method for drying a wetted molded product of pasty high viscous composition which comprises subjecting the molded product to a dehydration process while wholly or partially contacting the product with an open-cell foamed hydrophobic porous membrane.

Abstract: A sustained-release preparation of indomethacin or interferon comprising the active ingredient in admixture with a pharmaceutically acceptable biodegradable carrier, particularly a carrier selected from collagen, gelatin, and a mixture thereof. Said preparation is particularly suitable for parenteral administration and can release the active ingredient in an effective amount for a long period of time.

Abstract: A solid sustained-release preparation in the form of a needle-like or bar-like shape, which consists essentially of an active ingredient and a pharmaceutically acceptable biodegradable carrier (e.g. proteins, preferably collagen, gelatin, and a mixture thereof). The sustained release preparation can be administered to the body or implanted into the body by injection or an injection-like method and can release the active ingredient at an effective level for a long period of time when administered.

Abstract: The invention relates to sustained pulsewise release pharmaceutical preparation which comprices drug-containing polymeric material layers (layers A) and polymeric material layers containing the drug in question only in a slight amount or free of the drug (layers B) disposed alternatingly, with the whole surface extending in the direction perpendicular to the layer plane being coated with a polymeric material which is insoluble in water or scarcely soluble in water (polymeric material C).This pharmaceutical preparation of this invention is designed so that active ingredients which should desirably be released pulsewise can be released therefrom in a pulse-like and clinically significant manner and thereby the pharmacological effects of said active ingredients can be maintained for a prolonged period of time.

Abstract: A sustained release composition applicable for human beings and mammals which comprises (a) a silicone elastomer and (b) a pharmaceutical substance optionally with (c) albumin. When the pharmaceutical substance is of high molecular weight, and can exert its pharmaceutical effect in a trace amount, its continuous release over a long period is attained by application of this invention.

Abstract: Growth hormone releasing factor (GRF) preparation which is excellent in stablity by having human serum albumin or glycine incorporated therein, with or without buffer. An amount of human serum albumin or glycine contained is usually 100 .mu.g to 30 mg per 100 .mu.g GRF. The preparation may be in the solid or solution form, preferably in the lyophilized form. An amount of buffer, if added, is preferably enough so that pH of the preparation is kept at 2-7. More preference is that the preparation is kept in nitrogen gas atmosphere. The lyophilized preparation is readily usable for, for example, injection.

Abstract: A device for administering solid or semisolid preparations under the skin, which comprises a solid needle member with an acute tip end, and a cylindrical member slidably mounted on the needle member. The solid needle member having a recess at its front part to form a preparation chamber between the needle member and cylindrical member, and the chamber being opened or closed by moving the cylindrical member in the direction parallel to the axis of the needle member. The device may comprises a cylindrical member with a capsule chamber, a hollow needle member removable mounted on the front end of the cylindrical member, and a plunger slidably arranged in the capsule chamber of the cylindrical member, all of which have a common axis so that the plunger enters into the hollow needle member through the capsule chamber.

Abstract: An antimicrobial preparation of D-7-[.alpha.-(4-hydrooxy-6-methylnicotinamido)-4-hydroxyphenylacetamido]-3 -(1-methyltetrazol-5-yl)thiomethyl-.DELTA..sup.3 -cephem-4-sodium carboxylate (hereinafter referred to as "Compound A" of enhanced stability is disclosed, which comprises a microbially effective amount of Compund A and a stabilizer selected from the class consisting of benzoic acid, sodium benzoate and nicotinamide.

Abstract: A sustained-release preparation of indomethacin or interferon comprising the active ingredient in admixture with a pharmaceutically acceptable biodegradable carrier, particularly a carrier selected from collagen, gelatin, and a mixture thereof. The preparation is particularly suitable for parenteral administration and can release the active ingredient in an effective amount for a long period of time.

Abstract: A method for preparing a sustained release formulation utilizing collagen and/or gelatin as a carrier, which comprises the steps:(i) preparing a uniform and high concentrated mixture with respect to the collagen and/or gelatin by blending an active ingredient, said collagen and/or gelatin, and water or an admixture consisting of water and a hydrophilic organic solvent under one of the conditions selected from:(A) the pH of the mixture is kept below 5 and the salt concentration of the mixture is retained below fiber-forming concentration;(B) chemically modified collagen and/or gelatin is employed; and(C) glucose is added to the mixture;(ii) molding the resultant mixture; and(iii) gradually eliminating the solvent from the molded product.

Abstract: A composition comprising as the pharmaceutically active ingredient bencyclane fumarate and cyclodextrin.As compared with prior bencyclane fumarate preparations, this composition can greatly decrease the adverse effects of bencyclane fumarate and, in addition, offers considerable advantages from the viewpoints of method of use and method of production of preparation.

Abstract: A method for preparing a stable urokinase injection by the liophilization of urokinase which comprises liophilizing an aqueous solution containing urokinase, human serum albumin and one or more amino acid compounds selected from polar amino acids and salt thereof. The urokinase injection obtained according to this method is excellent in the storing stability as compared with conventional urokinase preparations for injection.

Abstract: A process for freeze-drying a penicillin derivative of the formula: ##STR1## wherein R is a hydrogen atom or a hydroxyl group, by evaporating a frozen aqueous solution of the penicillin derivative (I) under vacuum from the frozen state to dryness, which is characterized by maintaining the temperature of the frozen solution within a range from the eutectic point of the solution determined by the electric resistance method to -8.degree. C. when the penicillin derivative of the formula (I) wherein R is a hydrogen atom is to be freeze-dried, or -10.degree. C. when the penicillin derivative of the formula (I) wherein R is a hydroxyl group is to be freeze-dried during the primary drying period of the drying process.